NLRP3 and cancer: Though, further studies are needed to clarify whether, based on the current knowledge related to the involvement of the NLRP3 inflammasome in cancer progression and cancer-therapy (doxorubicin, CAR T cells, checkpoint inhibitors,...)-related cardiac toxicity and side effects, this statement also accounts for anti-IL-1ß drugs as combination therapy with an anti-cancer treatment.